A Phase 2 interventional study of Ruxolitinib 0.15% Cream QD and Ruxolitinib 0.5% Cream QD in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 52 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 77 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 3 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
17 studies in Dermatitis, Atopic by Incyte Corporation: 2 open now, 3 under way, 1 of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2017, is one of 4 in phase 2, and was the 1st registered.
Incyte Corporation’s Dermatitis, Atopic studies by the year they started, since 2017.
1 of the studies testing ruxolitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661979Wake Forest University Health SciencesOpzelura Experience Study | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 17 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with cytopenias at screening, defined as:
Participants with severely impaired liver function ( Class C) or end-stage renal disease (ESRD) on dialysis or at least 1 of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
Drug: Vehicle Cream BID
Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
Drug: Triamcinolone 0.1% Cream BID · Drug: Vehicle Cream BID
Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
Drug: Ruxolitinib 0.15% Cream QD
Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
Drug: Ruxolitinib 0.5% Cream QD
Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
Drug: Ruxolitinib 1.5% Cream QD
Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
Drug: Ruxolitinib 1.5% Cream BID
Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
Drug: Ruxolitinib 1.5% Cream BID
Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
Drug: Ruxolitinib 1.5% Cream BID
Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
Drug: Ruxolitinib 1.5% Cream BID
Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
Drug: Ruxolitinib 1.5% Cream BID
Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
Drug: Ruxolitinib 1.5% Cream BID
Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
Drug: Ruxolitinib 1.5% Cream BID
Ruxolitinib 0.15% cream QD
Also known as: INCB018424
Ruxolitinib 0.5% cream QD
Also known as: INCB018424
Ruxolitinib 1.5% cream QD
Also known as: INCB018424
Ruxolitinib 1.5% cream BID
Also known as: INCB018424
Triamcinolone 0.1% cream BID
Vehicle cream BID
Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
Time frame: Baseline and Week 4
Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD Compared With Participants Treated With Vehicle Cream BID
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
Time frame: Baseline and Week 4
Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD/BID Cream Compared With Participants Treated With Triamcinolone 0.1% Cream BID Followed by Vehicle
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
Time frame: Baseline and Week 4
Mean Percentage Change From Baseline in EASI Score at Week 2 and Week 8
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
Time frame: Baseline, Week 2 and 8
Percentage of Participants Who Achieve a ≥ 50% Improvement From Baseline in EASI (EASI-50) at Weeks 2, 4, and 8
The categorical variable EASI-50 will be equal to 1 for percentage improvement from baseline in EASI score of 50% or greater and will be equal to 0 for percentage improvement of less than 50%. This definition is introduced for the purpose of identifying participants who respond to the treatment (1 = responder, 0 = non-responder).
Time frame: Week 2, 4 and 8
Percentage Change From Baseline in EASI Score at Week 4
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
Time frame: Baseline and Week 4
Time to Achieve EASI-50
Time to EASI-50 is defined as the interval between the time of randomization and the time of achieving at least 50% improvement in EASI score.
Time frame: From Baseline to Week 8
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points From Baseline at Weeks 2, 4, and 8
IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). An IGA responder was defined as a participant achieving an IGA score of 0 to 1 and an IGA score improvement at least 2 from baseline.
Time frame: Week 2, 4 and 8
Mean Change From Baseline in the Itch Numerical Rating Scale (NRS) Score at Weeks 2, 4, and 8
The Itch NRS is a once-per-24 hours ("daily") participant-reported measure of itch intensity to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The categorical NRS is defined as 0 = None, 1 to 3 = Mild, 4 to 6 = Moderate, and 7 to 10 = Severe.
Time frame: Baseline, Week 2, 4 and 8
Number of Participants With At Least One Adverse Event (AEs) and as Per Severity
AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4.Data are reported for Grade 3 and higher severity for this outcome measure.
Time frame: Up to Week 24
A total of 307 participants were randomized and 306 were treated at 50 study centers in the United States and Canada from 9 January 2017 to 12 March 2018.
| Milestone | Double Blind (DB): Vehicle BID | DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% Once Daily (QD) | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID | Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID | OL: TAC BID/ Vehicle BID to Ruxolitinib 1.5% BID | OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 1.5% Cream BID for 8 Weeks in DB Period. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 52 | 51 | 51 | 51 | 52 | 50 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated in db period | 52 | 51 | 51 | 51 | 51 | 50 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed treatment through week 4 | 44 | 46 | 48 | 47 | 49 | 49 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 41 | 41 | 45 | 44 | 45 | 45 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 11 | 10 | 6 | 7 | 7 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 2 | 5 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 1 | 2 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Double Blind (DB): Vehicle BID | DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% Once Daily (QD) | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID | Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID | OL: TAC BID/ Vehicle BID to Ruxolitinib 1.5% BID | OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 1.5% Cream BID for 8 Weeks in DB Period. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 40 | 45 | 41 | 42 | 43 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 37 | 43 | 41 | 40 | 40 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 2 | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 2 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| percent change | DB: Vehicle BID | DB: Ruxolitinib 1.5% BID |
|---|---|---|
| Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID | -11.90 ± 6.65 | -71.57 ± 6.42 |
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| percent change | DB: Vehicle BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD |
|---|---|---|---|---|
| Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD Compared With Participants Treated With Vehicle Cream BID | -11.90 ± 6.65 | -44.92 ± 6.47 | -52.80 ± 6.52 | -66.72 ± 6.36 |
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| percent change | DB: TAC 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|
| Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD/BID Cream Compared With Participants Treated With Triamcinolone 0.1% Cream BID Followed by Vehicle | -59.54 ± 6.53 | -44.92 ± 6.47 | -52.80 ± 6.52 | -66.72 ± 6.36 | -71.57 ± 6.42 |
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| percent change | DB: Vehicle BID | DB: TAC 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|---|
| Week 2 | -4.84 ± 5.34 | -39.94 ± 5.29 | -29.96 ± 5.23 | -45.88 ± 5.41 | -49.88 ± 5.18 | -52.68 ± 5.29 |
| Week 8 | -21.86 ± 7.09 | -58.02 ± 6.94 | -50.24 ± 6.82 | -58.37 ± 6.93 | -67.05 ± 6.72 | -79.01 ± 6.83 |
The categorical variable EASI-50 will be equal to 1 for percentage improvement from baseline in EASI score of 50% or greater and will be equal to 0 for percentage improvement of less than 50%. This definition is introduced for the purpose of identifying participants who respond to the treatment (1 = responder, 0 = non-responder).
| percentage of participants | DB: Vehicle BID | DB: TAC 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|---|
| Week 2 | 13.5 | 43.1 | 31.4 | 57.1 | 50.0 | 52.0 |
| Week 4 | 23.1 | 66.7 | 52.9 | 58.8 | 73.1 | 78.0 |
| Week 8 | 26.9 | 60.8 | 54.9 | 62.7 | 69.2 | 76.0 |
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| percent change | DB: Vehicle BID | DB: TAC 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|---|
| Percentage Change From Baseline in EASI Score at Week 4 | -15.5 ± 65.71 | -59.8 ± 35.71 | -45.4 ± 53.96 | -52.2 ± 48.32 | -67.0 ± 26.28 | -71.6 ± 25.27 |
Time to EASI-50 is defined as the interval between the time of randomization and the time of achieving at least 50% improvement in EASI score.
| week | DB: Vehicle BID | DB: TAC 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|---|
| Time to Achieve EASI-50 | 4 (0 to 8) | 2 (0 to 8) | 4 (0 to 8) | 2 (0 to 8) | 2 (0 to 8) | 2 (0 to 8) |
IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). An IGA responder was defined as a participant achieving an IGA score of 0 to 1 and an IGA score improvement at least 2 from baseline.
| percentage of participants | DB: Vehicle BID | DB: TAC 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|---|
| Week 2 | 1.9 | 11.8 | 5.9 | 4.1 | 13.5 | 8.0 |
| Week 4 | 7.7 | 25.5 | 9.8 | 13.7 | 21.2 | 38.0 |
| Week 8 | 9.6 | 17.6 | 15.7 | 31.4 | 30.8 | 48.0 |
The Itch NRS is a once-per-24 hours ("daily") participant-reported measure of itch intensity to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The categorical NRS is defined as 0 = None, 1 to 3 = Mild, 4 to 6 = Moderate, and 7 to 10 = Severe.
| score on scale | DB: Vehicle BID | DB: TAC 0.1% BID/ Vehicle BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|---|
| Baseline | 6.0 ± 2.11 | 5.2 ± 2.22 | 6.1 ± 2.23 | 6.2 ± 1.71 | 6.2 ± 2.14 | 5.9 ± 2.25 |
| Change from Baseline at Week 2 | -0.7 ± 1.46 | -2.2 ± 1.75 | -1.9 ± 1.97 | -2.5 ± 2.23 | -3.1 ± 2.14 | -3.7 ± 2.56 |
| Change from Baseline at Week 4 | -1.0 ± 1.79 | -2.5 ± 1.94 | -2.3 ± 2.08 | -2.6 ± 2.22 | -3.3 ± 2.24 | -4.0 ± 2.89 |
| Change from Baseline at Week 8 | -1.2 ± 2.13 | -2.2 ± 1.86 | -3.0 ± 2.49 | -2.9 ± 2.41 | -3.8 ± 2.39 | -4.2 ± 2.91 |
AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4.Data are reported for Grade 3 and higher severity for this outcome measure.
| Participants | DB: Vehicle BID | DB: TAC 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% QD | DB: Ruxolitinib 0.5% QD | DB: Ruxolitinib 1.5% QD | DB: Ruxolitinib 1.5% BID | OL: Vehicle BID to Ruxolitinib 1.5% BID | OL: TAC BID/Vehicle Cream BID to Ruxolitinib 1.5% BID | OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID | OL: Ruxolitinib 1.5% BID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At Least One AE | 17 | 17 | 19 | 11 | 17 | 12 | 5 | 11 | 11 | 8 | 11 | 17 |
| Grade 3 and Higher | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
Collected over Up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle BID | 0/52 (0%) | 0/52 (0%) | 10/52 (19.2%) |
| Triamcinolone 0.1% BID for 4 Weeks Then 4 Week Vehicle BID | 0/51 (0%) | 1/51 (2%) | 3/51 (5.9%) |
| INCB018424 0.15% QD | 0/51 (0%) | 0/51 (0%) | 6/51 (11.8%) |
| INCB018424 0.5% QD | 0/51 (0%) | 0/51 (0%) | 2/51 (3.9%) |
| INCB018424 1.5% QD | 0/51 (0%) | 0/51 (0%) | 6/51 (11.8%) |
| INCB018424 1.5% BID | 0/259 (0%) | 0/259 (0%) | 23/259 (8.9%) |
| Event | Vehicle BID | Triamcinolone 0.1% BID for 4 Weeks Then 4 Week Vehicle BID | INCB018424 0.15% QD | INCB018424 0.5% QD | INCB018424 1.5% QD | INCB018424 1.5% BID |
|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/52 | 1/51 | 0/51 | 0/51 | 0/51 | 0/259 |
| Event | Vehicle BID | Triamcinolone 0.1% BID for 4 Weeks Then 4 Week Vehicle BID | INCB018424 0.15% QD | INCB018424 0.5% QD | INCB018424 1.5% QD | INCB018424 1.5% BID |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/52 | 0/51 | 3/51 | 1/51 | 4/51 | 13/259 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 4/52 | 2/51 | 1/51 | 0/51 | 2/51 | 4/259 |
| Upper respiratory tract infectionInfections and infestations | 3/52 | 1/51 | 2/51 | 1/51 | 1/51 | 7/259 |
Intent-to-Treat (ITT) population included all participants who are randomized to the study.
| Age, Continuous(years) | Double Blind (DB): Vehicle BID | DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% Once Daily (QD) | DB : Ruxolitinib 0.5% QD | DB : Ruxolitinib 1.5% QD | DB : Ruxolitinib 1.5% Cream Twice Daily (BID) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 34.8 ± 15.04 | 38.5 ± 16.19 | 38.4 ± 13.83 | 38.6 ± 13.73 | 39.1 ± 14.54 | 39.0 ± 15.72 | 38.1 ± 14.82 |
| Sex: Female, Male(Participants) | Double Blind (DB): Vehicle BID | DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% Once Daily (QD) | DB : Ruxolitinib 0.5% QD | DB : Ruxolitinib 1.5% QD | DB : Ruxolitinib 1.5% Cream Twice Daily (BID) | Total |
|---|---|---|---|---|---|---|---|
| Female | 32 | 28 | 26 | 27 | 31 | 24 | 168 |
| Male | 20 | 23 | 25 | 24 | 21 | 26 | 139 |
| Race/Ethnicity, Customized(Participants) | Double Blind (DB): Vehicle BID | DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% Once Daily (QD) | DB : Ruxolitinib 0.5% QD | DB : Ruxolitinib 1.5% QD | DB : Ruxolitinib 1.5% Cream Twice Daily (BID) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 8 | 2 | 3 | 1 | 3 | 20 |
| Not Hispanic or Latino | 47 | 43 | 49 | 48 | 51 | 47 | 285 |
| Other | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Double Blind (DB): Vehicle BID | DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID | DB: Ruxolitinib 0.15% Once Daily (QD) | DB : Ruxolitinib 0.5% QD | DB : Ruxolitinib 1.5% QD | DB : Ruxolitinib 1.5% Cream Twice Daily (BID) | Total |
|---|---|---|---|---|---|---|---|
| White/Caucasian | 27 | 28 | 27 | 33 | 24 | 33 | 172 |
| Black/African-American | 15 | 13 | 17 | 10 | 17 | 13 | 85 |
| Asian | 8 | 8 | 5 | 8 | 10 | 2 | 41 |
| Native Hawaiian/Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 1 | 2 | 2 | 0 | 1 | 2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Jan 2018, 12 months.
Results were first posted in Apr 2021, 3 years 2 months after primary completion. A results delay was requested in Jan 2019.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib